Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epidermal growth factor reduces hepatic sequelae in experimental necrotizing enterocolitis.

Melissa D Halpern1, Hana Holubec, Jessica A Clark

  • 1Department of Pediatrics, Steele Children's Research Center, University of Arizona, Tucson, Ariz., USA. mhalpern@peds.arizona.edu

Biology of the Neonate
|December 2, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel immunohistochemical assay utilizing the INSM1 (SP493) antibody demonstrates high specificity and sensitivity in detecting primary neuroendocrine lung neoplasms.

Diagnostic pathology·2025
Same author

Extracellular Nicotinamide Phosphoribosyltransferase Is a Therapeutic Target in Experimental Necrotizing Enterocolitis.

Biomedicines·2024
Same author

Global Frequency Analyses of Canine Progressive Rod-Cone Degeneration-Progressive Retinal Atrophy and Collie Eye Anomaly Using Commercial Genetic Testing Data.

Genes·2023
Same author

<i>Clostridium scindens</i> exacerbates experimental necrotizing enterocolitis via upregulation of the apical sodium-dependent bile acid transporter.

American journal of physiology. Gastrointestinal and liver physiology·2023
Same author

Enteral Feeding and Antibiotic Treatment Do Not Influence Increased Coefficient of Variation of Total Fecal Bile Acids in Necrotizing Enterocolitis.

Newborn (Clarksville, Md.)·2023
Same author

Investigation of a common canine factor VII deficiency variant in dogs with unexplained bleeding on autopsy.

Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·2022

Epidermal growth factor (EGF) supplementation in neonatal rats with necrotizing enterocolitis (NEC) normalized liver cytokine overproduction. This suggests EGF positively impacts the gut-liver axis, reducing intestinal damage in experimental NEC.

Area of Science:

  • Neonatal physiology
  • Gastroenterology
  • Immunology

Background:

  • Neonatal necrotizing enterocolitis (NEC) is a critical gastrointestinal disease in premature infants.
  • The gut-liver axis and inflammatory mediators are implicated in NEC pathogenesis.
  • Epidermal growth factor (EGF) has previously shown promise in reducing ileal pathology in experimental NEC.

Purpose of the Study:

  • To investigate the effects of EGF on the liver component of the gut-liver axis in a neonatal rat model of NEC.
  • To determine if EGF supplementation influences liver inflammation and related signaling pathways during NEC development.

Main Methods:

  • Newborn rats were assigned to three groups: NEC (formula-fed), NEC + EGF (formula supplemented with EGF), and dam-fed (DF) controls.
  • NEC was induced via twice-daily asphyxia and cold stress for four days.

Related Experiment Videos

  • EGF receptor expression, Kupffer cell counts, and hepatic cytokine levels (TNF-alpha, IL-18) were analyzed.

    • Main Results:

    • EGF supplementation significantly decreased EGF receptor expression in the NEC+EGF group compared to the NEC group.
    • EGF significantly reduced Kupffer cell numbers and hepatic TNF-alpha and IL-18 production.
    • Intestinal TNF-alpha levels in the NEC+EGF group were normalized to control levels, and activated NF-kappaB was decreased.

    Conclusions:

    • EGF administration normalizes hepatic cytokine overproduction in neonatal rats experiencing experimental NEC.
    • These findings suggest EGF supplementation benefits the gut-liver axis, mitigating intestinal damage during NEC.
    • EGF holds potential as a therapeutic strategy for NEC by modulating liver inflammation.